Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Zillow Group Inc Class C (Z) Price & Performance

Merck & Co., Inc.Trade
Zillow Group Inc Class CTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Zillow Group Inc Class C — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while Zillow Group Inc Class C trades at $33.24 (market cap $7.68B). The key difference: Merck & Co., Inc. is far larger — about 41.9× Zillow Group Inc Class C's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.

MRKZ
Market Cap
$321.77B$7.68B
Sector
HealthMedia
52-Week High
$131.84$90.35
52-Week Low
$77.60$29.41
Enterprise Value
$368.53B$7.56B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Zillow Group Inc Class C

Zillow Group (Z) trades at $33.26, down 1.45% on the day, amid a bearish technical signal and mixed sentiment. The stock shows strong revenue growth, with Q2 2026 results beating expectations, but faces near-term pressure from a securities class action lawsuit. Valuation metrics like a P/E of 148.41 reflect high growth expectations, while profitability remains modest with a net income margin of 1.96%.

The outlook is cautious; analyst consensus targets $52.00, implying upside, but legal risks and a challenging real estate market pose headwinds. Investors should weigh the company's monetization progress against litigation overhangs and macroeconomic sensitivity for balanced risk-reward assessment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Zillow Group Inc Class C

Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.

Read more on Z